Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Prospective Clinical Trial to Investigate Safety, Tolerability, Maximum Tolerated Dose and Anti-tumor Effect for SCO-101 in Combination With FOLFIRI as a Safe and Efficient Treatment Modality in Metastatic or Advanced Colorectal Cancer (mCRC) Patients With Acquired FOLFIRI Resistant Cancer Disease.

NCT04247256 is registered in ClinicalTrials.gov with Scandion Oncology A/S as lead sponsor.

NCT NCT04247256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04247256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Prospective Clinical Trial to Investigate Safety, Tolerability, Maximum Tolerated Dose and Anti-tumor Effect for SCO-101 in Combination With FOLFIRI as a Safe and Efficient Treatment Modality in Metastatic or Advanced Colorectal Cancer (mCRC) Patients With Acquired FOLFIRI Resistant Cancer Disease.
Lead sponsor
Scandion Oncology A/S
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 14, 2020
Completion date
June 30, 2022
Enrollment
35 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer